Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Randomized Study of CNS Prophylaxis in ALL (DepoCyte vs Triple IT Therapy)
2007-006652-19Phase 2Completed
- Sponsor
- Northern Italy Leukemia Group
- Start
- Apr 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of liposomal cytarabine in B cell acute lymphoblastic leukemia (B-ALL), acute lymphoblastic leukemia (ALL), precursor B-lymphoblastic lymphoma (B-LBL) and 1 more (2 arms), sponsored by Northern Italy Leukemia Group. Primary endpoints: Feasibility of intrathecal DepoCyte vs triple intrathecal therapy, Toxicity of intrathecal DepoCyte vs triple intrathecal therapy and 1 more. Started Apr 2008; status: completed.
02
Drugs
liposomal cytarabine
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)acute lymphoblastic leukemia (ALL)precursor B-lymphoblastic lymphoma (B-LBL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on 2007-006652-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006652-19.